COVID-19: Pharmidex Contingency Plan
March 19, 2020

Pharmidex are taking all the necessary steps to ensure the progression of client studies during these difficult time.

COVID-19: Pharmidex Contingency Plan


We are taking all necessary steps to ensure that studies proceed, while preserving the health and safety of staff. Summary of key steps taken at Pharmidex:


- Following the relevant guidelines issued by Public Health England.


- Limiting access to only essential people in our laboratories and cancelling/rescheduling all non-critical visitors. All visitors must confirm COVID-19 status prior to arrival.


- Cancelled all non-essential business travel.


- Closely communicating with suppliers regarding the status of their inventories and their business continuity plans and identifying alternate sources for supplies.


- Implemented strict sanitization practices to prevent cross contamination between staff, including providing our staff with resources and up-to-date information and guidance.


- To prevent the potential spread of the infection amongst employees, staff will declare any potential close contact with infected individuals and follow the relevant health guidelines.


- Our operations team will ensure adequate staffing cover so as not to compromise client studies.


We will keep you updated if the situation changes resulting in any impact on progression of your projects.


Best wishes to everyone during these tough times.

May 20, 2026
We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.
May 19, 2026
Pharmidex is pleased to announce that Janette Dalay Robertson , Business Development Manager, will be attending the Milner Seminar May 2026 hosted by the Milner Therapeutics Institute at the Jeffrey Cheah Biomedical Centre , Cambridge, on 19 May 2026 from 4:00–5:00pm. The seminar will bring together experts from academia and industry to discuss innovation and collaboration in drug discovery and translational science. Pharmidex will also be exhibiting at the event. Janette will be near the café in the Jeffrey Cheah Biomedical Centre from 11am tomorrow, so if you would like to discuss drug discovery, preclinical development, bioanalysis, or potential collaborations, please feel free to stop by for a chat before the seminar begins. Looking forward to connecting with researchers, biotech innovators, and industry partners throughout the day!
May 18, 2026
We’re pleased to highlight Gaurang Patel and his extensive expertise in clinical and bioanalytical research. With more than 19 years of experience spanning analytical development, method validation, and regulatory-compliant environments, Gaurang brings deep scientific knowledge and operational leadership to every programme. His commitment to robust analytical methods, laboratory excellence, quality, and compliance continues to support the delivery of reliable, efficient, and audit-ready outcomes across complex research projects. At Pharmidex , we value the experience and dedication that help drive scientific progress and trusted partnerships.
More Posts